VTGN News and Press, VistaGen Therapeutics Inc. From 07/22/21

VistaGen Therapeutics (VTGN) announces the appointment of Maggie FitzPatrick to the company's board of directors.FitzPatrick replaces Brian Underdown who recently retired from the board.Recently, she served as a member of the Exelon Corporation executive committee. ...

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and ...

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central ...

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno...

VistaGen Therapeutics ([[VTGN]] -1.8%) has appointed Mary Rotunno to its board of directors.Rotunno is currently general counsel at El Camino Health.Prior to El Camino, she was senior counsel at Common Spirit Health, formerly Dignity Health.VistaGen is focused on developing therapies for anxi...

VistaGen Therapeutics Inc. (NASDAQ:VTGN) traded today at a new 52-week high of $3.50. Approximately 1.8 million shares have changed hands today, as compared to an average 30-day volume of 3 million shares. In the past 52 weeks, shares of VistaGen Therapeutics Inc. have traded between a l...

VistaGen Therapeutics Inc. (NASDAQ:VTGN) traded today at a new 52-week high of $3.27. So far today approximately 1.8 million shares have been exchanged, as compared to an average 30-day volume of 3 million shares. VistaGen Therapeutics Inc. share prices have moved between a 52-week high ...

Shares of VistaGen Therapeutics (NASDAQ: VTGN) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and provided a corporate update after the market close on Tuesday. It wasn't VistaGen's finan...

These Current & Former Biotech Penny Stocks Have Seen A Strong Year So Far One of the great things about biotech penny stocks is the potential of these companies. There are very few places that offer this kind of early access to potentially life-saving treatments. If you take a ...